Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer.

NCT06474806 is registered in ClinicalTrials.gov with Curasight as lead sponsor.

NCT NCT06474806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06474806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer.
Lead sponsor
Curasight
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2024
Completion date
January 30, 2027
Enrollment
168 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer